Clinical trial
A Prospective, Single-Arm, Multicenter Clinical Study of Epalolitoworelimab (a PD-1/CTLA-4 Combination Antibody) Combined With Lenvatinib in the Perioperative Treatment of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma
NCT07741617 is registered in ClinicalTrials.gov with The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Single-Arm, Multicenter Clinical Study of Epalolitoworelimab (a PD-1/CTLA-4 Combination Antibody) Combined With Lenvatinib in the Perioperative Treatment of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma
- Lead sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- August 15, 2026
- Completion date
- August 15, 2030
- Enrollment
- 54 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.